With only one company set to list this month, it appears that the volatility that surrounds the ASX is prompting some companies to delay listing until some degree of normality in financial markets is restored. One company brave enough to face the current environment is Atomo Diagnostics Limited (Proposed ASX: AT1). The Sydney-based medical diagnostics
Read More
As the world battles the coronavirus pandemic, G Medical (ASX: GMV) has secured authorisation from the Food and Drug Administration to sell their Prizma smartphone attachment direct to customers without the need for a prescription, rocketing the company’s share price. Prizma, a smartphone attachment which can monitor a user’s vital signs, can play a vital
Read More
Prior to COVID-19 bringing attention to the value of telehealth, HeraMED (ASX: HMD) has been building digital infrastructure to revolutionise the maternal healthcare market with their screening and remote midwife platform which is preparing to now enter the lucrative U.S market. The expansion into the world’s most lucrative healthcare market, valued at USD $111 billion
Read More
Medtech company RhinoMed (ASX: RNO) will soon be significantly increasing its product shelf space in the United States having secured a distribution deal with CVS for its new over-the-counter (OTC) sleep aid product – Pronto Sleep. With the company forecasting the sleep aids market to reach $66.3 billion by 2021, RhinoMed’s interest focuses on OTC
Read More
Australian medtech company Cyclopharm (ASX: CYC) is set to add the United States to the list of 59 countries which have approved Technegas®, its nuclear functional ventilation imaging agent, having lodged its New Drug Application (NDA) with the Food and Drug Administration (FDA). As the world’s largest nuclear medicine market in the world, the opportunity
Read More
As coronavirus fears continue to grip the global economy, send markets deep into the red and see a global shutdown of mass gatherings, technology will play a vital role in keeping the world interconnected, whilst in isolation. Panic buying has sent demand for healthcare products rocketing, leading to strong gains from medical product manufacturers but
Read More